The power and the promise of liver cancer stem cell markers

Stem Cells and Development

Volumn 20, Issue 12, 2011, Pages 2023-2030

  Liu, Li Li ^a   Fu, Da ^a   Ma, Yushui ^a   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; CD133 ANTIGEN; CELL MARKER; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HOE 33342; MICROSOMAL AMINOPEPTIDASE; MULTIDRUG RESISTANCE PROTEIN 1; THY 1 ANTIGEN; TUMOR MARKER;

CANCER PATIENT; CANCER STEM CELL; CANCER TISSUE; CELL SELECTION; DRUG EFFICACY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; LIVER CANCER STEM CELL; LIVER CELL CARCINOMA; LIVER PARENCHYMA; MAGNETIC ACTIVATED CELL SORTING; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOPLASTIC STEM CELLS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 82455168183     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0012     Document Type: Review

References (81)

1. Farazi PA and RA DePinho2006). Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 6:674-687.
2. Jemal A, R Siegel, E Ward, Y Hao, J Xu, T Murray and MJ Thun2008). Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
3. Lobo NA, Y Shimono, D Qian and MF Clarke2007). The biology of cancer stem cells. Annu Rev Cell Dev Biol 23: 675-699.
4. Dick JE and T Lapidot2005). Biology of normal and acute myeloid leukemia stem cells. Int J Hematol 82:389-396.
5. + HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27:1749-1758.
6. Lapidot T, C Sirard, J Vormoor, B Murdoch, T Hoang, J Caceres-Cortes, M Minden, B Paterson, MA Caligiuri and JE Dick1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645-648.
7. Bonnet D and JE Dick1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737.
8. Visvader JE and GJ Lindeman2008). Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768.
9. Chiba T, K Kita, YW Zheng, O Yokosuka, H Saisho, A Iwama, H Nakauchi and H Taniguchi2006). Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. Hepatology 44:240-251.
10. + hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351:820-824.
11. Yin S, J Li, C Hu, X Chen, M Yao, M Yan, G Jiang, C Ge, H Xie, et al2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120:1444-1450.
12. Ma S, KW Chan, L Hu, TK Lee, JY Wo, IO Ng, BJ Zheng and XY Guan2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556.
13. + population in hepatocellular carcinoma. Int J Cancer 126:2067-2078.
14. Yang ZF, DW Ho, MN Ng, CK Lau, WC Yu, P Ngai, PW Chu, CT Lam, RT Poon and ST Fan2008). Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell 13:153-166.
15. Yang ZF, P Ngai, DW Ho, WC Yu, MN Ng, CK Lau, ML Li, KH Tam, CT Lam, RT Poon and ST Fan2008). Identification of local and circulating cancer stem cells in human liver cancer. Hepatology 47:919-928.
16. Yamashita T, M Forgues, W Wang, JW Kim, Q Ye, H Jia, A Budhu, KA Zanetti, Y Chen, et al2008). EpCAM and alpha- Fetoprotein Expression Defines Novel Prognostic Subtypes of Hepatocellular Carcinoma. Cancer Res 68:1451-1461.
17. Yamashita T, J Ji, A Budhu, M Forgues, W Yang, HY Wang, H Jia, Q Ye, LX Qin, et al2009). EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/ progenitor cell features. Gastroenterology 136:1012-1024.
18. Yang W, HX Yan, L Chen, Q Liu, YQ He, LX Yu, SH Zhang, DD Huang, L Tang, et al2008). Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. Cancer Res 68:4287-4295.
19. Ma S, KW Chan, TK Lee, KH Tang, JY Wo, BJ Zheng and XY Guan2008). Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Mol Cancer Res 6:1146-1153.
20. Haraguchi N, H Ishii, K Mimori, F Tanaka, M Ohkuma, HM Kim, H Akita, D Takiuchi, H Hatano, et al2010). CD13 is a therapeutic target in human liver cancer stem cells. J Clin Invest 120:3326-3339.
21. Hadnagy A, L Gaboury, R Beaulieu and D Balicki2006). SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312:3701-3710.
22. Challen GA and MH Little2006). A side order of stem cells: the SP phenotype. Stem Cells 24:3-12.
23. Haraguchi N, T Utsunomiya, H Inoue, F Tanaka, K Mimori, GF Barnard and M Mori2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24:506-513.
24. Shi GM, Y Xu, J Fan, J Zhou, XR Yang, SJ Qiu, Y Liao, WZ Wu, Y Ji, et al2008). Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol 134:1155-1163.
25. Chiba T, S Miyagi, A Saraya, R Aoki, A Seki, Y Morita, Y Yonemitsu, O Yokosuka, H Taniguchi, H Nakauchi and A Iwama2008). The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res 68:7742-7749.
26. Hu C, H Li, J Li, Z Zhu, S Yin, X Hao, M Yao, S Zheng and J Gu2008). Analysis of ABCG2 expression and side population identifies intrinsic drug efflux in the HCC cell line MHCC-97L and its modulation by Akt signaling. Carcinogenesis 29:2289-2297.
27. Zen Y, T Fujii, S Yoshikawa, H Takamura, T Tani, T Ohta and Y Nakanuma2007). Histological and culture studies with respect to ABCG2 expression support the existence of a cancer cell hierarchy in human hepatocellular carcinoma. Am J Pathol 170:1750-1762.
28. Yin AH, S Miraglia, ED Zanjani, G Almeida-Porada, M Ogawa, AG Leary, J Olweus, J Kearney and DW Buck1997). AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002-5012.
29. Hemmati HD, I Nakano, JA Lazareff, M Masterman-Smith, DH Geschwind, M Bronner-Fraser and HI Kornblum2003). Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A 100:15178-15183.
30. Singh SK, ID Clarke, M Terasaki, VE Bonn, C Hawkins, J Squire and PB Dirks2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
31. Li C, DG Heidt, P Dalerba, CF Burant, L Zhang, V Adsay, M Wicha, MF Clarke and DM Simeone2007). Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037.
32. O'Brien CA, A Pollett, S Gallinger and JE Dick2007). A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110.
33. Ricci-Vitiani L, DG Lombardi, E Pilozzi, M Biffoni, M Todaro, C Peschle and R De Maria2007). Identification and expansion of human colon-cancer- initiating cells. Nature 445:111-115.
34. Collins AT, PA Berry, C Hyde, MJ Stower and NJ Maitland2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951.
35. + liver cancer stem cells from methionine adenosyl transferase 1A-deficient mice demonstrate resistance to transforming growth factor (TGF)-beta-induced apoptosis. Hepatology 49:1277-1286.
36. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 67:1-5.
37. Platet N, SY Liu,ME Atifi, L Oliver, FMVallette, F Berger and D Wion2007). Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 258:286-290.
38. You H, W Ding and CB Rountree2010). Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 51:1635-1644.
39. Yao J, T Zhang, J Ren, M Yu and G Wu2009). Effect of CD133/prominin-1 antisense oligodeoxynucleotide on in vitro growth characteristics of Huh-7 human hepatocarcinoma cells and U251 human glioma cells. Oncol Rep 22:781-787.
40. Kohga K, T Tatsumi, T Takehara, H Tsunematsu, S Shimizu, M Yamamoto, A Sasakawa, T Miyagi and N Hayashi2010). Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 52:872-879.
41. Tsuchiya A, H Kamimura, M Takamura, S Yamagiwa, Y Matsuda, Y Sato, M Nomoto, T Ichida and Y Aoyagi2009). Clinicopathological analysis of CD133 and NCAM human hepatic stem/progenitor cells in damaged livers and hepatocellular carcinomas. Hepatol Res 39:1080-1090.
42. + parenchymal cells in the liver: histology and culture. World J Gastroenterol 15:4896-4906.
43. Kemper K, MR Sprick, M de Bree, A Scopelliti, L Vermeulen, M Hoek, J Zeilstra, ST Pals, H Mehmet, G Stassi and JP Medema2010). The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 70:719-729.
44. Rege TA and JS Hagood2006). Thy-1 as a regulator of cellcell and cell-matrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 20:1045-1054.
45. Dan YY, KJ Riehle, C Lazaro, N Teoh, J Haque, JS Campbell and N Fausto2006). Isolation of multipotent progenitor cells from human fetal liver capable of differentiating into liver and mesenchymal lineages. Proc Natl Acad Sci U S A 103:9912-9917.
46. Cho RW, X Wang, M Diehn, K Shedden, GY Chen, G Sherlock, A Gurney, J Lewicki and MF Clarke2008). Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 26:364-371.
47. Zhao H and DM Peehl2009). Tumor-promoting phenotype of CD90hi prostate cancer-associated fibroblasts. Prostate 69:991-1000.
48. + cancer stem cells in glioblastoma. Mol Cancer 5:67.
49. Lara-Pezzi E, JM Serrador, MC Montoya, D Zamora, M Yanez-Mo, M Carretero, H Furthmayr, F Sanchez-Madrid and M Lopez-Cabrera2001). The hepatitis B virus X protein (HBx) induces a migratory phenotype in a CD44-dependent manner: possible role of HBx in invasion and metastasis. Hepatology 33:1270-1281.
50. Du L, H Wang, L He, J Zhang, B Ni, X Wang, H Jin, N Cahuzac, M Mehrpour, Y Lu and Q Chen2008). CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 14:6751-6760.
51. + cells with cancer stem cell characteristics. Breast Cancer Res 10:R10.
52. Takaishi S, T Okumura, S Tu, SS Wang, W Shibata, R Vigneshwaran, SA Gordon, Y Shimada and TC Wang2009). Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 27:1006-1020.
53. Hirohashi K, T Yamamoto, T Uenishi, M Ogawa, K Sakabe, S Takemura, T Shuto, H Tanaka, S Kubo and H Kinoshita2004). CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology 51:1121-1123.
54. Endo K and T Terada2000). Protein expression of CD44 (standard and variant isoforms) in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, p53 expression, and patient survival. J Hepatol 32: 78-84.
55. Tanaka M, M Okabe, K Suzuki, Y Kamiya, Y Tsukahara, S Saito and A Miyajima2009). Mouse hepatoblasts at distinct developmental stages are characterized by expression of EpCAM and DLK1: drastic change of EpCAM expression during liver development. Mech Dev 126:665-676.
56. Schmelzer E, L Zhang, A Bruce, E Wauthier, J Ludlow, HL Yao, N Moss, A Melhem, R McClelland, et al2007). Human hepatic stem cells from fetal and postnatal donors. J Exp Med 204:1973-1987.
57. Schmelzer E, E Wauthier and LM Reid2006). The phenotypes of pluripotent human hepatic progenitors. Stem Cells 24:1852-1858.
58. Munz M, PA Baeuerle and O Gires2009). The Emerging Role of EpCAM in Cancer and Stem Cell Signaling. Cancer Res 69:5627-5629.
59. Terris B, C Cavard and C Perret2010). EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma. J Hepatol 52:280-281.
60. Yamashita T, A Budhu, M Forgues and XW Wang2007). Activation of hepatic stem cell marker EpCAM by Wnt-betacatenin signaling in hepatocellular carcinoma. Cancer Res 67:10831-10839.
61. Hashida H, A Takabayashi, M Kanai, M Adachi, K Kondo, N Kohno, Y Yamaoka and M Miyake2002). Aminopeptidase N is involved in cell motility and angiogenesis: its clinical significance in human colon cancer. Gastroenterology 122:376-386.
62. Petrovic N, W Schacke, JR Gahagan, CA O'Conor, B Winnicka, RE Conway, P Mina-Osorio and LH Shapiro2007). CD13/APN regulates endothelial invasion and filopodia formation. Blood 110:142-150.
63. Christ B, P Stock and MM Dollinger2011). CD13: Waving the flag for a novel cancer stem cell target. Hepatology 53:1388-1390.
64. Moreb JS2008). Aldehyde dehydrogenase as a marker for stem cells. Curr Stem Cell Res Ther 3:237-246.
65. Jiang F, Q Qiu, A Khanna, NW Todd, J Deepak, L Xing, H Wang, Z Liu, Y Su, SA Stass and RL Katz2009). Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 7:330-338.
66. Ginestier C, MH Hur, E Charafe-Jauffret, F Monville, J Dutcher, M Brown, J Jacquemier, P Viens, CG Kleer, et al2007). ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567.
67. Hixson DC, L Chapman, A McBride, R Faris and L Yang1997). Antigenic phenotypes common to rat oval cells, primary hepatocellular carcinomas and developing bile ducts. Carcinogenesis 18:1169-1175.
68. Bisgaard HC, DC Parmelee, HA Dunsford, S Sechi and SS Thorgeirsson1993). Keratin 14 protein in cultured nonparenchymal at hepatic epithelial cells: characterization of keratin 14 and keratin 19 as antigens for the commonly used mouse monoclonal antibody OV-6. Mol Carcinog 7:60-66.
69. Crosby HA, SG Hubscher, RE Joplin, DA Kelly and AJ Strain1998). Immunolocalization of OV-6, a putative progenitor cell marker in human fetal and diseased pediatric liver. Hepatology 28:980-985.
70. Becker G, A Schmitt-Graeff, V Ertelt, HE Blum and HP Allgaier2007). CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol) 19:204-208.
71. + tumor cells in hepatitis B virus-associated hepatocellular carcinoma. Am J Clin Pathol 124:31-36.
72. Fausto N2004). Liver regeneration and repair: hepatocytes, progenitor cells, and stem cells. Hepatology 39:1477-1487.
73. Kuhlmann WD and P Peschke2006). Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol 87:343-359.
74. Smith LM, A Nesterova, MC Ryan, S Duniho, M Jonas, M Anderson, RF Zabinski, MK Sutherland, HP Gerber, et al2008). CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100-109.
75. Wu X-Z and D Chen2006). Origin of hepatocellular carcinoma: role of stem cells. J Gastroenterol Hepatol 21:1093-1098.
76. Tomuleasa C, O Soritau, D Rus-Ciuca, T Pop, D Todea, O Mosteanu, B Pintea, V Foris, S Susman, G Kacso and A Irimie2010). Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. J Gastrointestin Liver Dis 19:61-67.
77. Yeh C-T, C-J Kuo, M-W Lai, T-C Chen, C-Y Lin, T-S Yeh and W-C Lee2009). CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 9:324-324.
78. Song W, H Li, K Tao, R Li, Z Song, Q Zhao, F Zhang and K Dou2008). Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 62:1212-1218.
79. Salnikov AV, G Kusumawidjaja, V Rausch, H Bruns, W Gross, A Khamidjanov, E Ryschich, MM Gebhard, G Moldenhauer, et al2009). Cancer stem cell marker expression in hepatocellular carcinoma and liver metastases is not sufficient as single prognostic parameter. Cancer Lett 275:185-193.
80. Yang XR, Y Xu, B Yu, J Zhou, SJ Qiu, GM Shi, BH Zhang, WZ Wu, YH Shi, et al2010). High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut 59:953-962.
81. Lingala S, YY Cui, X Chen, BH Ruebner, XF Qian, MA Zern and J Wu2010). Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 89:27-35.